Trial
NCT01548924
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators
Hospital Universitario de Fuenlabrada; M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge
Condition
Solid Tumors
Intervention
Dovitinib
Why stopped
Drug toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-17